These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 39055878)

  • 1. Suppression of TGF-β/Smad3 signaling pathway by
    Afarin R; Hatami M; Monjezi S; Bineshfar F; Ahangarpour A
    Iran J Basic Med Sci; 2024; 27(9):1096-1104. PubMed ID: 39055878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capparis spinosa improves non-alcoholic steatohepatitis through down-regulating SREBP-1c and a PPARα-independent pathway in high-fat diet-fed rats.
    Akbari R; Yaghooti H; Jalali MT; Khorsandi LS; Mohammadtaghvaei N
    BMC Res Notes; 2022 Oct; 15(1):315. PubMed ID: 36192786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capparis spinosa improves the high fat diet-induced non-alcoholic steatohepatitis in rats: the possible role of FGF21.
    Akbari R; Yaghooti H; Jalali MT; Khorsandi LS; Mohammadtaghvaei N
    BMC Res Notes; 2020 Jul; 13(1):356. PubMed ID: 32723353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis.
    Akbari R; Behdarvand T; Afarin R; Yaghooti H; Jalali MT; Mohammadtaghvaei N
    BMC Pharmacol Toxicol; 2021 Oct; 22(1):53. PubMed ID: 34593018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Danhe granule ameliorates nonalcoholic steatohepatitis and fibrosis in rats by inhibiting ceramide de novo synthesis related to CerS6 and CerK.
    Zhu M; Jia Z; Yan X; Liu L; Fang C; Feng M; Dai Y; Zhang Y; Wu H; Huang B; Li Y; Liu J; Xiao H
    J Ethnopharmacol; 2022 Sep; 295():115427. PubMed ID: 35654350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis of non-alcoholic fatty liver disease mediated by YAP.
    Chen P; Luo Q; Huang C; Gao Q; Li L; Chen J; Chen B; Liu W; Zeng W; Chen Z
    Hepatol Int; 2018 Jan; 12(1):26-36. PubMed ID: 29330836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation.
    Park HS; Song JW; Park JH; Lim BK; Moon OS; Son HY; Lee JH; Gao B; Won YS; Kwon HJ
    Autophagy; 2021 Sep; 17(9):2549-2564. PubMed ID: 33190588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigallocatechin gallate attenuated non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet.
    Ding Y; Sun X; Chen Y; Deng Y; Qian K
    Eur J Pharmacol; 2015 Aug; 761():405-12. PubMed ID: 25967348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mechanism of catgut embedding at back-
    Zhou XL; Tang N; Wu T; Zhang Y; Chen Q; Wei WH; Zhou YN; Zhang DX; Qin FC; Yang W
    Zhongguo Zhen Jiu; 2020 Jan; 40(1):59-66. PubMed ID: 31930901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tanshinone IIA regulates the TGF-β1/Smad signaling pathway to ameliorate non-alcoholic steatohepatitis-related fibrosis.
    Xu L; Zhang Y; Ji N; Du Y; Jia T; Wei S; Wang W; Zhang S; Chen W
    Exp Ther Med; 2022 Jul; 24(1):486. PubMed ID: 35761808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the anti-inflammatory and antilipidemic activity of diosmin and saroglitazar in a model of nonalcoholic fatty liver induced by a high-fat diet in Wistar rats.
    Afarin R; Dinarvand N; Jaberian Asl B; Orak G; Shakerian E; Bineshfar F; Ahangarpour A
    Iran J Basic Med Sci; 2024; 27(2):241-246. PubMed ID: 38234671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of curcumol on liver function and fibrosis in rats of nonalcoholic fatty liver disease and its mechanism].
    Qi SY; Huang H; Li YK; Pei LG; Zhang WJ
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2021 Nov; 37(6):611-615. PubMed ID: 34821093
    [No Abstract]   [Full Text] [Related]  

  • 13. Saroglitazar Deactivates the Hepatic LPS/TLR4 Signaling Pathway and Ameliorates Adipocyte Dysfunction in Rats with High-Fat Emulsion/LPS Model-Induced Non-alcoholic Steatohepatitis.
    Hassan NF; Nada SA; Hassan A; El-Ansary MR; Al-Shorbagy MY; Abdelsalam RM
    Inflammation; 2019 Jun; 42(3):1056-1070. PubMed ID: 30737662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neferine ameliorates nonalcoholic steatohepatitis through regulating AMPK pathway.
    Wang MY; Zhang SS; An MF; Xia YF; Fan MS; Sun ZR; Zhang LJ; Zhao YL; Sheng J; Wang XJ
    Phytomedicine; 2023 Jun; 114():154798. PubMed ID: 37031639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
    Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
    Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resveratrol and fenofibrate ameliorate fructose-induced nonalcoholic steatohepatitis by modulation of genes expression.
    Abd El-Haleim EA; Bahgat AK; Saleh S
    World J Gastroenterol; 2016 Mar; 22(10):2931-48. PubMed ID: 26973390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of Nrf2 and related factors on the progression of nonalcoholic steatohepatitis].
    Cai YQ; Zhang LZ; Wang DJ; Chen FM; Chen ZY; Zhu KY; Li JS; Yan MX
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2014 Sep; 30(5):465-70. PubMed ID: 25571645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
    Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis.
    Vijayakumar A; Okesli-Armlovich A; Wang T; Olson I; Seung M; Kusam S; Hollenback D; Mahadevan S; Marchand B; Toteva M; Breckenridge DG; Trevaskis JL; Bates J
    Hepatol Commun; 2022 Sep; 6(9):2298-2309. PubMed ID: 35735253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calycosin attenuates triglyceride accumulation and hepatic fibrosis in murine model of non-alcoholic steatohepatitis via activating farnesoid X receptor.
    Duan X; Meng Q; Wang C; Liu Z; Liu Q; Sun H; Sun P; Yang X; Huo X; Peng J; Liu K
    Phytomedicine; 2017 Feb; 25():83-92. PubMed ID: 28190475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.